◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
Home › All stocks › N › NBTX

Nanobiotix (NBTX) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-06

Nanobiotix (NBTX) operates in the BIOTECHNOLOGY industry and is headquartered in Paris, France with about 100 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, NBTX reported €30M in revenue and (€24M) in net income.

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.

Interactive charts & full statements → Open the NBTX valuation workbench →

NBTX Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2025-12-312025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-31
Total Revenue€30M€30M(€7M)€36M€5M€3M€2M€3M€3M€4M€5M€4M€3M€2M€1M€1M
Gross Profit€30M€30M(€7M)€36M€5M€3M€2M€3M€3M€4M€5M€4M€3M€2M€1M€1M
Gross Margin %100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%
Operating Income (EBIT)(€11M)(€11M)(€68M)(€27M)(€47M)(€53M)(€36M)(€47M)(€30M)(€25M)(€22M)(€17M)(€10M)(€8M)(€5M)(€5M)
Operating Margin %-36.5%-36.5%951.2%-74.0%-977.8%-1986.4%-1566.8%-1841.0%-864.2%-678.9%-403.1%-426.9%-347.2%-512.7%-530.9%-384.3%
Net Income(€24M)(€24M)(€68M)(€40M)(€57M)(€47M)(€34M)(€51M)(€30M)(€26M)(€22M)(€17M)(€10M)(€8M)(€5M)(€5M)
Net Margin %-80.8%-80.8%947.6%-109.6%-1194.3%-1775.7%-1444.7%-2003.7%-872.2%-702.4%-403.6%-423.5%-344.9%-510.5%-549.2%-385.7%
EBITDA(€12M)(€12M)(€68M)(€24M)(€44M)(€46M)(€35M)(€45M)(€29M)(€25M)(€21M)(€17M)(€9M)(€8M)(€5M)(€5M)
Earnings Per Share (EPS)€-0.50€-0.50€-1.44€-1.08€-1.64€-1.35€-1.38€-2.35€-1.55€-1.50€-1.43€-1.20€-0.74€-0.76€-0.65€-3.42
Shares Outstanding (M)48M48M47M37M35M35M24M22M20M17M15M14M13M11M8M2M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NBTX Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2025-12-312025-06-302025-03-312024-06-302024-03-312023-09-302023-06-302023-03-31
Total Revenue€3M€27M(€16M)€9M€33M€16M€3M€3M
Gross Profit€3M€27M(€16M)€9M€33M€16M€3M€3M
Gross Margin %100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%
Operating Income (EBIT)(€12M)€1M(€45M)(€24M)(€1M)€1M(€25M)(€21M)
Operating Margin %-386.9%3.0%271.5%-254.6%-4.3%3.5%-770.4%-604.1%
Net Income(€19M)(€5M)(€46M)(€22M)(€12M)(€6M)(€28M)(€31M)
Net Margin %-618.2%-20.2%280.7%-235.5%-35.2%-35.2%-853.3%-890.2%
EBITDA(€13M)€1M(€44M)(€23M)€2M€1M(€25M)(€20M)
Earnings Per Share (EPS)€-0.39€-0.11€-0.98€-0.46€-0.30€-0.15——
Shares Outstanding (M)48M47M47M47M39M39M——

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NBTX Free Cash Flow History

Cash flowTTM → 2025-12-312025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-31
Cash from Operations (CFO)(€33M)(€33M)(€20M)(€12M)(€37M)(€30M)(€28M)(€41M)(€26M)(€21M)(€18M)(€17M)(€9M)(€7M)(€4M)(€5M)
Capital Expenditures (CapEx)€1M€1M€1M€0M€0M€0M€0M€1M€0M€1M€0M€1M€1M€0M€0M€0M
Free Cash Flow (FCF)(€34M)(€34M)(€20M)(€13M)(€37M)(€30M)(€28M)(€42M)(€26M)(€22M)(€19M)(€18M)(€10M)(€7M)(€4M)(€5M)
FCF Margin %-114.6%-114.6%283.7%-35.4%-778.8%-1137.1%-1188.6%-1663.1%-758.9%-598.8%-344.6%-456.1%-343.9%-440.4%-391.7%-358.2%
Dividends Paid—€0M€0M€0M€0M€0M€0M€0M€0M———€1M—€1M—

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NBTX Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2025-12-312025-06-302025-03-312024-06-302024-03-312023-09-302023-06-30
Cash from Operations (CFO)(€16M)(€17M)(€14M)(€6M)€5M€2M(€17M)
Capital Expenditures (CapEx)€0M€0M€0M€0M€0M€0M€0M
Free Cash Flow (FCF)(€16M)(€18M)(€14M)(€6M)€5M€2M(€18M)
FCF Margin %-546.0%-65.9%85.4%-68.1%14.6%14.6%-534.4%

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NBTX Balance Sheet History

Balance sheet2025-12-312025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-31
Total Assets€68M€68M€67M€94M€60M€102M€134M€56M€46M€57M€30M€26M€37M€7M€14M€3M
Cash & Cash Equivalents€53M€53M€50M€75M€41M€84M€119M€35M€36M€47M€21M€17M€33M€5M€12M€1M
Total Liabilities€152M€152M€133M€96M€87M€75M€64M€58M€32M€14M€13M€11M€7M€4M€3M€2M
Total Debt (Short + Long-Term)€93M€93M€48M€47M€49M€41M€44M€39M€20M€5M€6M(€1M)(€1M)(€1M)€0M€0M
Total Shareholders' Equity(€84M)(€84M)(€66M)(€2M)(€27M)€27M€70M(€2M)€14M€44M€17M€16M€30M€3M€11M€1M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NBTX viewer.

Other Companies in BIOTECHNOLOGY

← NBTRAll “N” companiesNBXG →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.